See the DrugPatentWatch profile for tigecycline

Based on the information available, Tigecycline is not a first-line treatment for Clostridium difficile (C. difficile) infections. According to the Centers for Disease Control and Prevention (CDC) [1], the first-line treatments for C. difficile infections are metronidazole and vancomycin.

However, a study published in the Journal of Antimicrobial Chemotherapy [2] suggests that Tigecycline may have some activity against C. difficile. The study found that Tigecycline was active against 96.2% of C. difficile isolates tested. However, the study also notes that Tigecycline is not a first-line treatment for C. difficile infections and that further studies are needed to determine its role in the treatment of these infections.

It is worth noting that Tigecycline is not listed as a recommended treatment for C. difficile infections on the DrugPatentWatch.com website [3], which provides information on approved and investigational drugs.

In conclusion, while Tigecycline may have some activity against C. difficile, it is not a first-line treatment for C. difficile infections. Further studies are needed to determine its role in the treatment of these infections.

Sources:

* [Centers for Disease Control and Prevention (CDC)]: <https://www.cdc.gov/drugresistance/biggest-threats.html>
* [Journal of Antimicrobial Chemotherapy]: <https://academic.oup.com/jac/article/61/5/1155/840838>
* [DrugPatentWatch.com]: <https://www.drugpatentwatch.com/>